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Fibromyalgia and depression might represent two manifestations of aﬀective spectrum disorder. They share similar pathophysiol-
ogy and are largely targeted by the same drugs with dual action on serotoninergic and noradrenergic systems. Here, we review
evidence for genetic and environmental factors that predispose, precipitate, and perpetuate ﬁbromyalgia and depression and
include laboratory ﬁndings on the role of depression in ﬁbromyalgia. Further, we comment on several aspects of ﬁbromyalgia
whichsupportthedevelopmentofreactivedepression,substantiallymoresothaninotherchronicpainsyndromes.However,while
sharingmanyfeatureswithdepression,ﬁbromyalgiaisassociatedwithsomaticcomorbiditiesandabsolutelydeﬁnedbyﬂuctuating
spontaneous widespread pain. Fibromyalgia may, therefore, be more appropriately grouped together with other functional pain
disorders, while psychologically distressed subgroups grouped additionally or solely with aﬀective spectrum disorders.
1.Introduction
The primary and debilitating symptom of ﬁbromyalgia (FM)
is widespread spontaneous pain. The ACR 1990 criteria also
included a demonstration of tenderness. Recently revised
diagnostic criteria have delegated the symptom of tenderness
to a list of frequent symptoms that include fatigue, lack
of refreshing sleep, cognitive impairments, abdominal
discomfort, and headache [1]. This list also includes
depression, which is prominent in ﬁbromyalgia with a
lifetime prevalence of about 90% for depressive symptoms
and 62–86% for major depressive disorder (MDD) [2–5].
At any point in time, the best estimate of cooccurrence
of depressive symptoms in FM is 40% [6]. The high
occurrence of depression in FM has led to consideration
of common pathophysiologic mechanisms and to the
possible classiﬁcation of ﬁbromyalgia as one of the family of
aﬀective spectrum disorders that include many psychiatric
conditions such as MDD, generalized anxiety disorder and
posttraumatic stress disorder, and somatic conditions such
as irritable bowel syndrome and migraine [3, 7, 8].
There is compelling evidence to link ﬁbromyalgia and
depression. They cooccur, they share similar pathophysiol-
ogy, and the pharmacological treatment of each includes
(but is not limited to) the same dual serotoninergic and
noradrenergicagonistssuchasamitriptyline,duloxetine,and
milnacipran. These similarities support the concept that
depression and FM are “diﬀerential symptom presentations




The underlying processes of both depression and FM can
be characterized by the lifetime course in an individual
person. These processes can be organized by the three2 Pain Research and Treatment
“P”s of predisposing, precipitating, and perpetuating factors.
Considerable evidence suggests that genetic and environ-
mental factors predispose individuals to develop depression
or FM. Indeed, a fundamental property of the multiple
genetic associations with depression is not that these genes
cause depression but rather that they increase the risk of
developing depression in response to a precipitating event
[9]. The considerable evidence for increased vulnerability
to depression includes genes involved in the function of
serotonin, catecholamines, monoamines, CRF, glutamate,
and brain-derived neurotrophic factor [9, 12–16]. The
evidence suggests that these genes result in an intermediate
phenotype that increases the general risk of a psychiatric
disorder precipitated by an environmental stressor or other
triggering event [9, 13]. A similar concept has been proposed
for FM in which both genetic factors and environmental
events predispose individuals to develop FM in response to
a subsequent precipitating event. Genetic factors in FM are
implicated by familial prevalence [6, 8, 17, 18]. Converging
evidence suggests that a polymorphism in the serotonin
transporter (5-HTT) gene, implicated in MDD, may also be
implicated in FM [19, 20]. This genetic inﬂuence, the estab-
lished inﬂuence of environment, and gene/environmental
interactions may all predispose individuals to develop FM
and depression. Many of the precipitating events described
below, such as physical trauma or sexual abuse, also likely
contribute to a predisposed state.
Raphael et al. [18] have provided elegant evidence for the
separate and joint predisposition to develop FM and MDD.
In a community-based sample, they recruited individuals
with both, either, or no MDD and FM, essentially ﬁlling
4c e l l so fa2× 2 table of FM presence (y/n) for one
dimensionandMDDpresence(y/n)fortheotherdimension.
These four cells deﬁned subject categories, and the data of
interest were collected from all available adult ﬁrst-degree
relatives of these subjects. Unlike previous studies that used
reports of the primary subjects for data on relatives, this
study actually interviewed the relatives. The results support
a familial aggregation of FM and MDD. In comparison to
a baseline rate of MDD of 28.7% in relatives of subjects
without either MDD or FM, the rate of MDD in relatives
was 39.0% in subjects with MDD and 37.3% in subjects
with FM. Having both FM and MDD increased the rate of
MDD in relatives to 45.5%. Expressed as odds ratios (ORs)
in comparison to the groups that did not have either MDD
or FM, the FM and MDD were similar with ORs of 1.47 and
1.56, and the combination of both FM and MDD increased
the ORs of family MDD to 2.02.
The results of Raphael et al. [18] were interpreted
as support for FM as a depression spectrum disorder.
Interestingly, the linkage for FM and MDD was not found
forFMandanymooddisorderexcludingMDD.Theseresults
suggest a familial, likely genetic, linkage in the predisposition
for acquiring FM and MDD and also suggest that depressive
symptoms without MDD can be in reaction to the presence
of FM and not due to a linked common mechanism.
Once predisposed to develop FM or depression, these
syndromes can be precipitated by events ranging from
injury to psychosocial stressors [21, 22]. Cited physical
examples include physical trauma, illness, infections such
as HIV, surgery, and autoimmune disease and motor vehi-
cle accidents [7, 23]. Psychosocial stressors range from
catastrophic events such as war to sexual abuse and other
forms of emotional stress and trauma [7, 23]. Physical
and psychosocial workplace events can also trigger these
syndromes. Harkness et al. [24] documented precipitating
physicalworkplace,eventssuchasheavyliftingandrepetitive
motion, and psychosocial factors such as monotonous work
and low social support.
Once triggered, both depression and FM involve a
number of similar physiological mechanisms that likely
perpetuate these disorders. It is well known that the acute
response to stress, mobilizing the organism to deal with
potentially life-threatening events, is beneﬁcial if it remains
acute. If abnormally prolonged, the disruption of normal
bodily processes can lead to a number of disease states.
The acute stress response, detailed in numerous reports,
involves activation of the hypothalamic-pituitary-adrenal
(HPA) axis which is coupled to the autonomic and limbic
systems. Activation of the HPA system involves a chain of
events. Corticotrophin-releasing hormone (CRH) is secreted
by the hypothalamus, which results in pituitary secretion
of ACTH. This CRH eﬀect is synergistically augmented
by hypothalamic secretion of argininevasopressin (AVP).
Increased ACTH in turn stimulates adrenal secretion of
cortisol. Cortisol is a potent glucocorticoid that activates
cytoplasmic receptors throughout the body to ultimately
mobilize action and inhibit vegetative processes such as
reproduction and growth. The glucocorticoids also provide
negative feedback regulation of the HPA axis via multiple
pathways acting on the hypothalamus and pituitary. These
eﬀects of the HPA axis activation are integrated with the
locus ceruleus-norepinephrine system (LCNE) that activates
brain systems involved in aﬀect and anticipation, precipita-
tion, propagation and termination of stress-related activity
and activation of pain [25].
The pathophysiology of both stress-induced depression
and ﬁbromyalgia has been described in terms of the delete-
rious consequences of an acute stress response that persists
far beyond a normal duration, failing to “reset” after the
stressor is removed or terminated. The results have been
characterized by the eﬀects on cortisol secretion, which
interact with neurotransmitter systems and regulation of
fatigue, aﬀect, and pain, linking ﬁbromyalgia and the subsets
of depression described below.
3.Reactive,Melancholic,and
AtypicalDepression
The term “depression” is used nonspeciﬁcally in the
ﬁbromyalgia literature similar to the nonspeciﬁc use of
pain in the depression literature. The literature distinguishes
between depressive symptoms, which can be evaluated by
depression questionnaire instruments, and MDD, a diag-
nosis determined by an appropriately experienced clinician.
Depression in ﬁbromyalgia is not a unitary phenomenon.
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compounded by the multiple comorbidities of ﬁbromyalgia.
In a broader sense, having any type of pain or just
having a medical condition can lead to appropriate reactive
depression.DepressionmayalsotaketheformofaMDDthat
is physiologically linked to the mechanisms that perpetuate
FM. In this case depression and FM might be considered to
be parallel processes that share one or more predisposing,
precipitating, and perpetuating features. These scenarios
need not be mutually exclusive; depression and FM could
be linked at numerous physiological and psychological levels
that vary over the progression of the disorders.
This complexity is compounded by heterogeneity in
both FM and depression. Several studies have identiﬁed
FM subgroups [26–31], ﬁnding major groups without
psychological involvement and groups with considerable
psychological distress. These subgroups respond diﬀerently
to pharmacological treatments, for example, 5-HT3 receptor
antagonists have been shown to be eﬀective in patients
withoutpsychologicaldistressandineﬀectiveinpatientswith
psychological distress [30]. The features of these subgroups
and this diﬀerential response to treatment suggest that at
least a subset of ﬁbromyalgia patients may share features of
an aﬀective spectrum disorder.
Similar to ﬁbromyalgia, diagnostic criteria distinguish
three subtypes of MDD. The subtypes of melancholic and
atypical depression characterize 60% of all MDD and are
considered to be the prevalent types in FM [32, 33]. The
thirdsubtypeisMDDwithpsychoticfeatures.Arecentstudy
distinguished between melancholic and atypical depression
in 76 ﬁbromyalgia patients and observed that 40 met the
criteria for atypical depression and 27 met the criteria
for melancholic depression [32]. This distinction was not
associated with diﬀerences in FM characteristics save for
greater severity of depression in the melancholic depression
group.
4. Maturation of FM and Depression:
From Hypercortisolism and Melancholic
Depressionto Hypocortisolism
andAtypicalDepression
The presence of melancholic and atypical depression in
FM may represent a disease progression that also explains
variable ﬁndings of HPA axis function in FM. These
subtypes of MDD are associated with diﬀerent alterations
of HPA axis function; melancholic depression is associated
with augmented cortisol (hypercortisolism) response while
atypical depression is associated with a blunted secretion of
cortisol (hypocortisolism). Gold et al. [33] have proposed
a progression in ﬁbromyalgia in which the early stage
is associated with hypercortisolism incorporated with a
prolonged normal stress response and the greater depres-
sion severity of melancholic depression. Over time, this
augmented cortisol response is blunted to below normal
levels, leading to hypcortisolism and the clinical features of
atypical depression. This progression to ultimately atypical
depression and the preponderance of women in both FM
and atypical depression may lead to the ﬁnding of increased
frequency of atypical depression in FM [32]a n dp r e s e n t
implications for treatments targeted to the stages in this
progression.
5. Scenariosof LinkedFM andDepression
A physiological progression in FM and a transition from a
melancholic to an atypical depression suggest one of several
possible links between FM and depression. Aguglia et al.
[2] consider three possibilities. The ﬁrst is the reactive case
in which the presence of a chronic painful and disabling
disorder is a depressing event. The authors reject this
hypothesis because the incidence of depression in FM [3, 34]
is considerably higher than that in other comparable pain
conditions or diseases. We oﬀer counter arguments below.
Aguglia et al.’s [2] second possibility is that FM reﬂects a
subthreshold depression, an idea that they reject since many
FM patients are not depressed and do not become depressed.
Aguglia et al.’s [2] third possibility is that FM and
depression can be conceptualized as disorders with multiple
peripheral and central manifestations that might belong
to the same aﬀective spectrum [8]. The proposed under-
lying mechanisms that perpetuate this spectrum include
the mechanisms discussed above: alteration in HPA axis
function, altered serotoninergic and noradrenergic function,
and altered function of systems that involve substance P,
neurosteroids, and cytokines.
6. Laboratory Evidence for the Role
of Depressionin FM
A study by Bartley et al. [35] explored the association of
mood and ﬁbromyalgia by examining the eﬀect of FM on
aﬀective processing. Both FM patients and healthy con-
trols, 17 per group, viewed pleasant, neutral, and unpleas-
ant images and rated the pleasantness/unpleasantness and
arousal evoked by the pictures. A number of physiological
variables were recorded, and two-thirds of the pictures were
accompanied by white noise stimuli to induce eye blinks. In
comparisontocontrols,FMpatientsshowedgreaternegative
ratings, arousal, and EMG responses to the negative unpleas-
ant images but no diﬀerences in responses to the pleasant
images. These results, found also for olfactory stimuli [36],
suggest that the mechanisms that modulate mood in FM do
not result in an anhedonia, that is, a diminished ability to
experience pleasure, but rather increase the unpleasantness
of unpleasant material.
A number of laboratory studies have explored the
interaction of depression and evoked pain sensitivity in
ﬁbromyalgia. Several have examined sensitivity to electrical
stimuli at the spinal level. In an extension of previous
ﬁndings of enhanced nociceptive ﬂexion reﬂex (NFR) in
ﬁbromyalgia [37, 38], Ang et al. [39] explored the role of
depression in the NFR in 32 women with FM. The Patient
Health Questionnaire 8-item Depression Scale (PHQ-8) was
used to divide subjects into depressed (score > 9) and
nondepressed groups. An inverse association between the
NFR threshold and ratings of current pain was observed in4 Pain Research and Treatment
the nondepressed group (−3.9mA change in NFR threshold
per unit of current pain) but not in the depressed group
(0.07mA change in NFR threshold per unit of current
pain). These results suggest that the presence of depression
disruptedthepositiverelationshipbetweenratingsofcurrent
pain and NFR sensitivity in FM.
Neuroimaging studies have examined the inﬂuence of
depression on supraspinal responses to painful pressure
stimulation. Giesecke et al. [40] used the fMRI BOLD
method to evaluate cerebral responses evoked by painful
pressure applied to the thumb in 30 patients with FM.
Depression was assessed by the Center for Epidemiological
Studies Depression Scale (CES-D) and the Composite Inter-
national Diagnostic Interview (CIDI). Two analyses were
performed on the data. In the ﬁrst correlational analysis,
the brain activity evoked by a subjectively similar pressure
stimulus was computed for each subject for each voxel of
the brain. For each of the 30 subject scores at each voxel, a
linear regression was performed between each patient’s pain-
evoked fMRI activity and each patient’s depression score on
the CES-D. This resulted in a scatter plot in which each point
is a person, deﬁned by their depression score and the pain-
evoked activity at that brain location. Correcting appropri-
ately for multiple comparisons, there were signiﬁcant associ-
ationsinbilateralamygdalaandincontralateralinsula.Inthe
second, intra-group, analysis, 7 FM patients diagnosed with
MDD were matched to 7 FM patients without MDD and to
7 healthy control subjects. Equally painful stimuli, evoked
by signiﬁcantly less pressure in the FM groups, revealed
activations in the pain matrix observed in the full group
analysis above and in previous studies of painful thumb
pressure pain. In addition, in the MDD group, these stimuli
evoked activations in bilateral amygdala and contralateral
insula, regions implicated in aﬀective processing. The results
suggest that the presence of depression had no eﬀect on
the sensory-discriminative processing of pain stimulation
and had a selective eﬀect on brain regions that process the
aﬀective-motivational dimension of pain.
An additional study in this laboratory used a correla-
tional analysis to assess the inﬂuence of catastrophizing,
a putatively depression-driven cognitive style of attaching
overly negative interpretations to events [41, 42]. Since some
argue that this style is a variant of depression [43, 44], the
analysis controlled for depression, identifying brain regions
of evoked pain activity associated with a measure of catastro-
phizing (Coping Strategies Questionnaire). [43] Applying an
analysis strategy described above for Giesecke et al. [40], the
analysis both identiﬁed brain regions, in which activation by
painful thumb pressure was associated with catastrophizing,
and regions in which activation in response to painful
pressure was signiﬁcantly diﬀerent in groups with low or
high catastrophizing scores divided by a median split. The
results identiﬁed several brain regions in which pain evoked
bypressureto the thumb wasassociated withcatastrophizing
over a sample of 29 FM patients. These regions include
contralateral anterior cingulate cortex, medial frontal gyrus,
lentiform and ipsilateral middle frontal gyrus, secondary
somatosensory cortex, claustrum, and cerebellum. These
regionsdidnotoverlapwiththebrainregions(amygdalaand
insula) associated with depression in the study by Giesecke
et al. [40], likely because the analysis controlled for the
eﬀect of depression [41]. Signiﬁcantly greater activations
in high versus low catastrophizing groups were observed
in contralateral medial frontal gyrus and inferior parietal
lobule, and in ipsilateral medial frontal gyrus, superior
frontal gyrus, secondary somatosensory cortex, and anterior
cingulate cortex. One region, ipsilateral inferior parietal
lobule, showed signiﬁcantly greater activation in the low
catastrophizing group. Both analyses found eﬀects in con-
tralateral medial frontal gyrus and in ipsilateral secondary
somatosensory cortex. These combined results suggest that
catastrophizing is uniquely associated with brain regions
involved in attention to pain and pain aﬀective processing.
In another fMRI study in FM patients, depression and
catastrophizing were not associated with the eﬀects of
pressure stimulation in any brain region. [45]. However,
this study used randomly delivered stimuli of much shorter
duration, which might have served to maximize the sensory
saliency, and minimize the unpleasantness, of the stimulus-
evoked sensations.
7. Treatment Evidencefrom ClinicalTrials
Depression and FM also appear to be linked because drugs
with dual serotoninergic and noradrenergic action are used
to treat both conditions. The two prime examples are the
noradrenergic, serotoninergic reuptake inhibitors (NSRIs)
duloxetine and milnacipran, antidepressants approved
recently in the US for treatment of FM. These agents mimic
the dual action of amitriptyline, a tricyclic antidepressant
which has long been used to treat chronic pain, including
FM. One signiﬁcant advantage is that these recent agents
have a superior adverse-eﬀect proﬁle since they do not pos-
sess the well-known anticholinergic eﬀects of amitriptyline.
Classic analgesic studies of amitriptyline suggest that the
pain-relieving mechanism is independent of the antidepres-
sant eﬀects. Pain relief is accomplished at a much smaller
dose (25mg) than those used for depression (100–150mg),
andanalgesiceﬀectsareobservedafteroneweekoftreatment
while antidepressant eﬀects were usually observed after three
weeks of treatment. In addition, the pain-relieving eﬀects are
independent of the eﬀects on depression and are observed
in both depressed and nondepressed patients [46, 47]. The
recent trials of duloxetine and milnacipran also provide
evidence for a pain-relieving action of dual serotoninergic
and noradrenergic agonists, that is, independent of depres-
sion [48–51]. A recent secondary analysis of 4 clinical trials
of duloxetine in ﬁbromyalgia explored treatment eﬀects
in patients who were comorbid with MDD. This analy-
sis demonstrated the relative independence of MDD and
ﬁbromyalgiainthatthebaselinelevelofonedidnotaﬀectthe
treatmenteﬃcacy of the other [4]. A path analysis also found
predominant direct eﬀects of treatment on mood and pain.
These results suggest that the eﬀects of the NSRI duloxetine
on pain and MDD were mediated by independent mech-
anisms. However, the path analyses also showed indirect
eﬀects in which improved mood resulted in improved pain
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pain with unpleasantness and aﬀective dimensions, the indi-
rect eﬀects of mood are reasonable and practically expected.
Similarly, relieved pain can be expected to improve mood.
These indirect eﬀects may reﬂect the inﬂuence of reactive
depression elements in FM. Aguglia et al. [2] reject this sce-
nario above because FM has a higher incidence of depression
than similarly severe pain conditions or diseases. However,
we feel that this issue deserves close scrutiny. Although
comparative diseases (such as rheumatoid arthritis) may be
comparable on severity, they may not be comparable on
other disease features that more powerfully drive reactive
depression. There are several aspects of FM that would fuel
an augmented reactive depression in comparison to many
other pain or medical syndromes. The pain is widespread,
including by deﬁnition all four body quadrants and the axial
skeleton. Pain extent is likely associated with the incidence
and severity of depression. Manchikanti et al. [52]h a v e
shownthattheincidenceofMDDwas4%inacontrolgroup,
20% in a group with chronic pain in region of the body, and
32% in patients experiencing pain in more than one body
region. This type eﬀect might be assumed to be the highest
in FM, in which the whole body pain encompassing 5 major
regions would place it high on the function relating MDD to
an u m b e ro fb o d ys i t e s .
In addition to the extent, FM is characterized by signif-
icant spontaneous pain. In contrast, many pain conditions
are characterized less by spontaneous pain and more by
movement-evoked pain. The inability to alleviate pain
by quiescence or postural adjustment may contribute to
depression. Similarly, the extensive spontaneous pain of
FM is accompanied by a large number of symptoms and
comorbidities that likely contribute to the probability of
reactive depression.
Furthermore, unlike other conditions such as rheuma-
toid arthritis or pain conditions with physical correlates,
patients with ﬁbromyalgia suﬀer symptoms with minimal
objective signs. Many in the medical ﬁeld still deny the very
existence of FM, relegating it to general somatization or
other psychiatric processes. Patients feel that they are not
believed and must ﬁght for acceptance. This lack of credible
objective evidence for diagnosis or underlying mechanism
likely explain the enthusiastic embrace of recent ﬁndings
such as altered concentrations of substance P in CSF [53–
56] and evidence of altered CNS processing at spinal [37, 38]
and supraspinal [37, 38, 40, 48, 53–77] levels. It also is a very
reasonable explanation for increased frequency and severity
of reactive depression in FM.
Finally, in concert with the lack of objective signs,
patients with ﬁbromyalgia live with increased uncertainty
of what they have and their prospects for the future. Since
many features of depression are future-oriented (despair,
hopelessness), this uncertainty is likely linked to depression.
8. Summary
In summary, depression and FM share both common
features and diﬀerences at multiple physiological and psy-
chological levels. Clear evidence indicates a mutual predis-
position; for example, biologically based MDD is predicted
nearly equally by the presence of familial MDD or FM.
This mutual predisposition is likely due to a combination
of genetic and environmental factors [12, 19, 78–82]. These
predisposed individuals are particularly vulnerable to a
precipitating event that triggers FM or MDD. An injury,
motor vehicle accident, illness, or psychosocial stressor can
activate a cascade of events with potent, persistent conse-
quences. There is considerable support for the hypothesis
that these precipitating events trigger an appropriate acute
stress response, including increased CRH, AVP, ACTH, and
cortisol. The initial elevations in cortisol are associated with
a melancholic depression, and a gradual shift to hypocortisol
levels coincides with a shift from melancholic depressive
disorder to atypical depression disorder. FM has been
characterizedbybothloweredandelevatedwakeningcortisol
levels and associated with both melancholic and atypical
depression [81,83,84].TheHPA axis systemis complexwith
multiple regulating feedback loops. Although predisposed
by similar mechanisms, FM and MDD may be mediated by
distinctly diﬀerent alterations of HPA function. For example,
depressed mood may be due to internal dysregulation of
the HPA system while the persistent pain of FM may be
due to known cytokine-mediated HPA activation [85–87].
Similarly, involvement of systems mediated by serotonin and
norepinephrinemaybecommontobothFManddepression,
yet the diﬀerential eﬀects of NSRI and tricyclic treatments
suggestatleastdistinct diﬀerencesin thefunctioning ofthese
systems in these two disorders.
FM and depression are clearly intertwined at the experi-
ential and measurement level. An examination of depression
questionnaires reveals numerous somatic items that would
be endorsed by a person suﬀering from chronic pain.
Depression hurts or at least provokes responses similar to
hurt; for example, “I do not feel as well as I used to,”
“I ache all over.” Conversely, to have pain is depressing,
and the behavioral consequences of reduced activity and
social isolation compound negative mood. FM is not fully
endorsed by all clinicians and is mediated by unknown
mechanisms with unknown prognosis. The patient’s current
state is unknown and uncertain, and the future more so.
A persistent, intractable pain syndrome fuels helplessness
and despair. The interactions can become cyclical and self-
perpetuating. When treatments such as exercise or cognitive
behavioral methods are shown to be eﬀective, depression
can rob the initiative and the ability to comply with such
treatments.
FM has been included in the family of aﬀective spectrum
disorders (ASDs) that include other physical conditions such
as migraine and irritable bowel syndrome and numerous
psychiatric disorders such as attention-deﬁcit/hyperactivity
disorder, bulimia nervosa, dysthymic disorder, generalized
anxiety disorder, major depressive disorder (MDD), obses-
sivecompulsivedisorder,panicdisorder,posttraumaticstress
disorder, premenstrual dysphoric disorder, and social phobia
[3, 7, 8]. While sharing features such as predisposition to
developpsychiatricconditionssuchasMDD,FMalsoisasso-
ciated with a number of somatic comorbid conditions. With
the predominant symptom of widespread pain, FM may
be grouped also with other functional pain disorders such6 Pain Research and Treatment
as temporomandibular pain disorders, Gulf War syndrome,
and vulvodynia as well as irritable bowel syndrome and
migraine. All of these may be expected to have some eﬀects
on common physiological systems such as dysregulation
of the HPA axis, autonomic functions, and of systems
regulating serotonin and norepinephrine. This commonality
may reﬂect both the widespread role of these systems in
health and disease and the limited repertoire of physiological
responses to multiple sources of pathophysiology. Disparate
mechanisms may result in similar symptoms, representing
components of a stereotypic stress response as described by
Selye [88]. The independence of treatment eﬀects suggests
that depression and FM are mediated by largely independent
mechanisms with mutual modulation of speciﬁc symptoms.
The widespread pain that characterizes FM suggests associa-
tion with a family of somatic disorders, while psychologically
distressed subgroups, requiring diﬀerent treatment, may
represent the additional or sole association with a family of
aﬀective spectrum disorders.
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